Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2020—Cepheid received emergency use authorization from the FDA for its Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses that cause COVID-19, flu A, flu B, and RSV infections from a single patient sample.
November 2020—Siemens Healthineers received FDA emergency use authorization for the SARS-CoV-2 IgG antibody test. It is the first antibody test authorized with a semiquantitative detection claim.
November 2020—ARUP Laboratories’ formula for ARUP Transport Media is now available to other laboratories. The formula is provided at the end of an article about an ARUP and University of Utah Health study in which the transport media was used for specimen collection (Hanson KE, et al. J Clin Microbiol. Accepted manuscript. Published online Aug. 12, 2020. doi:10.1128/JCM.01824-20).
November 2020—Bio-Rad Laboratories launched its in vitro diagnostics Virotrol SARS-CoV-2 and Viroclear SARS-CoV-2 positive and negative quality controls for use in antibody testing of SARS-CoV-2. The serological controls are available for in vitro assay procedures in the U.S. and are CE marked for IVD markets outside the U.S.
N0vember 2020—Bionano Genomics has launched the Bionano Prep SP Tissue and Tumor Kit, a DNA isolation kit developed for analysis of tumors and tissue with the company’s Saphyr system. The kit has been designed to simplify isolation of ultra-high-molecular-weight DNA from a variety of solid tumors and tissue types.
November 2020—Thermo Fisher Scientific announced the availability of its Oncomine Myeloid Assay GX, the first in a series of clinical research assays available from the company’s new portfolio of hematology-oncology assays for the Ion Torrent Genexus System.
November 2020—The FDA has issued an emergency use authorization for Visby Medical’s single-use personal PCR device, a rapid test for detecting COVID-19.
November 2020—Alpha-Tec Systems has released quality control slides containing smears of red blood cells infected with a mixture of ring-form, trophozoite, and schizont stages of Plasmodium falciparum. The slides are prefixed with methanol and are ready to stain with traditional Giemsa, Wright’s, or Field stains.
November 2020—DiaSorin Molecular received FDA clearance for its Simplexa Flu A/B & RSV Direct Gen II kit. The assay can be run alone or alongside the Simplexa COVID-19 Direct kit, allowing for differential diagnosis of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus.
November 2020—Qiagen plans to launch a test that can detect SARS-CoV-2 antigens in people with active infections in less than 15 minutes and process, on average, 30 swab samples per hour using a small digital detection system. The test is expected to become available in the fourth quarter of this year.
